Brokerages Set Stryker Co. (NYSE:SYK) PT at $381.16

Stryker Co. (NYSE:SYK) has received a consensus rating of “Moderate Buy” from the nineteen analysts that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $381.16.

Several equities research analysts have recently weighed in on SYK shares. Barclays increased their price objective on Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Wolfe Research initiated coverage on shares of Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective on the stock. Truist Financial lifted their price objective on shares of Stryker from $345.00 to $370.00 and gave the company a “hold” rating in a research note on Monday, October 14th. Piper Sandler reiterated an “overweight” rating and set a $380.00 target price on shares of Stryker in a research note on Tuesday, September 10th. Finally, UBS Group boosted their price target on Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st.

Insider Activity

In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now owns 2,852 shares of the company’s stock, valued at approximately $949,716. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now owns 2,852 shares of the company’s stock, valued at $949,716. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 220,068 shares of company stock worth $71,811,372 in the last 90 days. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Several hedge funds have recently bought and sold shares of the stock. Chicago Partners Investment Group LLC lifted its holdings in Stryker by 12.0% in the 4th quarter. Chicago Partners Investment Group LLC now owns 2,447 shares of the medical technology company’s stock valued at $753,000 after purchasing an additional 263 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Stryker during the fourth quarter valued at approximately $748,000. Integrated Advisors Network LLC boosted its position in Stryker by 10.6% during the fourth quarter. Integrated Advisors Network LLC now owns 3,342 shares of the medical technology company’s stock worth $1,001,000 after acquiring an additional 321 shares during the last quarter. Centaurus Financial Inc. grew its stake in Stryker by 10.9% in the 4th quarter. Centaurus Financial Inc. now owns 878 shares of the medical technology company’s stock worth $263,000 after acquiring an additional 86 shares during the period. Finally, Richardson Financial Services Inc. purchased a new stake in Stryker in the 4th quarter worth approximately $121,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 2.7 %

Shares of NYSE:SYK opened at $369.56 on Tuesday. The firm has a 50 day simple moving average of $355.79 and a 200-day simple moving average of $343.26. Stryker has a twelve month low of $255.22 and a twelve month high of $374.63. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $140.78 billion, a PE ratio of 42.19, a P/E/G ratio of 2.78 and a beta of 0.91.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.02. The business had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned $2.54 EPS. On average, equities analysts predict that Stryker will post 12 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.